Benzimidazole derivatives and their use for modulating the GABA
The present application discloses novel benzimidazole derivatives and their use as modulators of the GABA A receptor complex. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.
1. A compound of general formula I:
or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein
R represents a pyridyl group; which pyridyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, hydroxy, hydroxyalkyl and alkoxy.
2. The compound according to claim 1 , an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein R represents
wherein one of X and Y represents N and the other of X and Y represents CH; and R 1 represents halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, hydroxy, hydroxyalkyl or alkoxy.
3. The compound according to claim 2 , an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein X represents N and Y represents CH, and R 1 represents halo or alkoxy.
4. The compound of claim 1 , which is
2-[1-(2′-Methoxy-[2,3′]bipyridinyl-4-yl)-1H-benzoimidazol-5-yl]-propan-2-ol;
2-[1-(2′-Chloro-[2,3′]bipyridinyl-4-yl)-1H-benzoimidazol-5-yl]-propan-2-ol;
2-[1-(3′-Fluoro-[2,4′]bipyridinyl-4-yl)-1H-benzoimidazol-5-yl]-propan-2-ol;
4-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-[2,4′]bipyridinyl-3′-carbonitrile;
or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1 , or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
6. The compound of claim 1 , which is
2-[1-(2′-Chloro-[2,3′]bipyridinyl-4-yl)-1H-benzoimidazol-5-yl]-propan-2-ol;
or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof.